An Escherichia coli O157-specific engineered pyocin prevents and ameliorates infection by E. coli O157:H7 in an animal model of diarrheal disease

Jennifer M. Ritchie, Jennifer L. Greenwich, Brigid M. Davis, Roderick T. Bronson, Dana Gebhart, Steven R. Williams, David Martin, Dean Scholl, Matthew K. Waldor

Research output: Contribution to journalArticlepeer-review

47 Scopus citations

Abstract

AvR2-V10.3 is an engineered R-type pyocin that specifically kills Escherichia coli O157, an enteric pathogen that is a major cause of food-borne diarrheal disease. New therapeutics to counteract E. coli O157 are needed, as currently available antibiotics can exacerbate the consequences of infection. We show here that orogastric administration of AvR2-V10.3 can prevent or ameliorate E. coli O157:H7-induced diarrhea and intestinal inflammation in an infant rabbit model of infection when the compound is administered either in a postexposure prophylactic regimen or after the onset of symptoms. Notably, administration of AvR2-V10.3 also reduces bacterial carriage and fecal shedding of this pathogen. Our findings support the further development of pathogen-specific R-type pyocins as a way to treat enteric infections.

Original languageEnglish
Pages (from-to)5469-5474
Number of pages6
JournalAntimicrobial Agents and Chemotherapy
Volume55
Issue number12
DOIs
StatePublished - Dec 2011
Externally publishedYes

Fingerprint

Dive into the research topics of 'An Escherichia coli O157-specific engineered pyocin prevents and ameliorates infection by E. coli O157:H7 in an animal model of diarrheal disease'. Together they form a unique fingerprint.

Cite this